Disc Medicine (NASDAQ:IRON) Given Outperform Rating at Wedbush

Wedbush reaffirmed their outperform rating on shares of Disc Medicine (NASDAQ:IRON – Free Report) in a report issued on Monday morning, RTT News reports. Wedbush currently has a $43.00 price objective on the stock, down from their prior price objective of $84.00. Wedbush also issued estimates for Disc Medicine’s Q4 2024 earnings at ($1.19) EPS, […]

Related Keywords

Kevin Bitterman ,Raymond James ,Disc Medicine Inc ,Citigroup Inc ,Venture Fund Xlp Atlas ,Morgan Stanley ,Renaissance Technologies ,Cantor Fitzgerald ,Geode Capital Management ,Millennium Management ,Disc Medicine ,Free Report ,Moderate Buy ,Medicine Stock Down ,Get Free Report ,Director Kevin Bitterman ,Venture Fund ,Capital Management ,Point Capital Management ,Disc Medicine Daily ,Nasdaq Iron ,Iron ,Medical ,Reiterated Rating ,Wedbush ,